Fig 1: Clobetasol ameliorates behavioral impairment of CTB-Sap-induced MN ablation.a Repeated measures of a clinical score of motor impairment during the time-course of CTB-Sap-induced motoneuronal depletion in CTB-Sap vehicle and CTB-Sap clobetasol groups; data are shown as mean ± SEM of n = 12 mice per group; *p-value < 0.05 and **p-value < 0.01 between groups; two-way repeated-measures ANOVA. b Representative tracks of HC, CTB-Sap vehicle, and CTB-Sap clobetasol groups and quantification of the distance (expressed as mean meters ± SEM of n = 5 mice per time-point, as repeated measures) covered during 2 min performance on open-field grid walk test and quantification of the number of footfalls over a meter at -1, 7, 21 and 41 dpl in HC, CTB-Sap vehicle, and CTB-Sap clobetasol groups; data are shown as standard box-and-whiskers of n = 5 mice per group; *p-value < 0.05 and **p-value < 0.01 versus HC and between groups; two-way repeated-measures ANOVA. c–f Quantification and representative electromyographic profile of positive sharp waves (PSW, c and d), fibrillations (c and d), pseudo-neuromyotonia (NMT, c and e), and fasciculations (c and f) observed in denervated GM in CTB-Sap vehicle (black tracks in d–f) and CTB-Sap clobetasol groups (gray tracks in d–f); data are expressed as a number of events per second and showed as standard box-and-whiskers of n = 4 mice per group; measures were taken from distinct samples; *p-value < 0.05 versus CTB-Sap vehicle; two-sided Student’s t-test. g Representative pictures of AChE immunostaining and hematoxylin (HMX) and negative control (NC) on left GM of HC, CTB-Sap vehicle, and CTB-Sap clobetasol; scale bar: 25 µm. Dpl: days post lesion.